IRIS
Ingrasciotta, Ylenia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.769
EU - Europa 1.104
AS - Asia 1.072
SA - Sud America 432
AF - Africa 23
OC - Oceania 2
Totale 4.402
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.728
SG - Singapore 423
BR - Brasile 380
IE - Irlanda 321
SE - Svezia 249
CN - Cina 247
IT - Italia 163
VN - Vietnam 159
HK - Hong Kong 127
DE - Germania 101
PL - Polonia 81
RU - Federazione Russa 33
GB - Regno Unito 32
IN - India 27
AR - Argentina 22
FI - Finlandia 22
CA - Canada 19
RO - Romania 15
FR - Francia 13
MX - Messico 13
NL - Olanda 13
BE - Belgio 12
AT - Austria 10
UA - Ucraina 10
BD - Bangladesh 9
EC - Ecuador 9
IQ - Iraq 9
ID - Indonesia 8
JP - Giappone 8
UZ - Uzbekistan 8
VE - Venezuela 8
TR - Turchia 7
ES - Italia 6
BO - Bolivia 5
LT - Lituania 5
MA - Marocco 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
CI - Costa d'Avorio 4
BY - Bielorussia 3
CO - Colombia 3
CZ - Repubblica Ceca 3
EG - Egitto 3
IR - Iran 3
JO - Giordania 3
KG - Kirghizistan 3
PK - Pakistan 3
AE - Emirati Arabi Uniti 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
GR - Grecia 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CL - Cile 1
CY - Cipro 1
DZ - Algeria 1
GE - Georgia 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KR - Corea 1
KW - Kuwait 1
KZ - Kazakistan 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SA - Arabia Saudita 1
SV - El Salvador 1
TJ - Tagikistan 1
TV - Tuvalu 1
TW - Taiwan 1
UY - Uruguay 1
Totale 4.402
Salva come PNG Salva come JPEG
Città #
Ashburn 332
Chandler 324
Dublin 321
Dallas 203
Singapore 195
Nyköping 140
Hong Kong 127
Dong Ket 106
Beijing 87
Warsaw 77
Messina 74
Los Angeles 57
Princeton 51
The Dalles 45
Medford 42
Munich 40
São Paulo 36
Ann Arbor 32
New York 31
Bremen 30
Des Moines 25
Redondo Beach 24
Ho Chi Minh City 23
Frankfurt am Main 18
Jacksonville 17
Boardman 15
Focsani 15
Rome 15
Rio de Janeiro 14
Belo Horizonte 13
Moscow 13
Brussels 12
Santa Clara 12
Tianjin 12
Buffalo 11
Washington 11
Cambridge 10
Curitiba 10
Dearborn 10
Helsinki 9
Wilmington 9
Falls Church 8
London 8
Milan 8
Phoenix 8
Tashkent 8
Tokyo 8
Brasília 7
Campinas 7
Chennai 7
Houston 7
Jakarta 7
Montreal 7
Pune 7
Atlanta 6
Hanoi 6
Ningbo 6
Nuremberg 6
Caltagirone 5
Chicago 5
Jinan 5
Juiz de Fora 5
Seattle 5
Shenyang 5
Abidjan 4
Amsterdam 4
Baku 4
Bauru 4
Brooklyn 4
Campos dos Goytacazes 4
Denver 4
Guangzhou 4
Haiphong 4
Ipatinga 4
La Paz 4
Manchester 4
Nanchang 4
Nanjing 4
Piracicaba 4
Santa Luzia 4
Stockholm 4
Taizhou 4
Uberlândia 4
Vancouver 4
Baghdad 3
Boston 3
Buenos Aires 3
Casablanca 3
Caxias do Sul 3
Contagem 3
Council Bluffs 3
Da Nang 3
Düsseldorf 3
Haikou 3
Hortolândia 3
Hyderabad 3
Jiaxing 3
Johannesburg 3
Joinville 3
Lancaster 3
Totale 2.927
Salva come PNG Salva come JPEG
Nome #
1. Real World Evidence vs. Real World Data: definizioni e razionale 195
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study 162
Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study 154
Psoriasis and psoriasiform reactions secondary to Immune Checkpoint Inhibitors 133
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study 131
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: A population-based study 129
Analgesic drug use in elderly persons: A population-based study in Southern Italy 123
Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? 118
How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016 113
Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset 109
12. Real World Evidence nelle valutazioni post‑marketing su farmaci generici e biosimilari 109
Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy 107
Real world use of antidiabetic drugs in the years 2011–2017: A population-based study from Southern Italy 105
Comparison of Direct Oral Anticoagulant Use for the Treatment of Non-Valvular Atrial Fibrillation in Pivotal Clinical Trials vs. the Real-World Setting: A Population-Based Study from Southern Italy 98
Adverse drug reactions associated with off-label use of ketorolac, with particular focus on elderly patients. An analysis of the Italian pharmacovigilance database and a population based study 96
Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy 95
Kidney disease in diabetic patients: From pathophysiology to pharmacological aspects with a focus on therapeutic inertia 94
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014 93
Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease 92
Medication is an additional source of phosphate intake in chronic kidney disease patients 92
Erratum: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: A population-based study (BMC Nephrology (2019) 20 (359) DOI: 10.1186/s12882-019-1554-0) 91
Biosimilars in Italy: What do real-world data reveal? 91
Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study 90
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project 90
Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies 89
Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries 85
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014 84
Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials 83
The economic burden of preventable adverse drug reactions: a systematic review of observational studies 82
Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments 82
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease 82
In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study 81
Antidepressants and the Risk of Cardiovascular Events in Elderly Affected by Cardiovascular Disease: A Real-Life Investigation From Italy 81
Pharmacokinetics of new oral anticoagulants: implications for use in routine care 78
The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy 76
Recent advances in the management of chemotherapy-induced neutropenia: Biosimilar granulocyte colony-stimulating factor use in Italy 71
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 67
Testing of Coding Algorithms for Inflammatory Bowel Disease Identification, as Indication for Use of Biological Drugs, Using a Claims Database from Southern Italy 66
Quanto sono utilizzati in Italia i farmaci biosimilari? Uno studio retrospettivo sull'uso degli agenti stimolanti l'eritropoiesi negli anni 2009-2013 62
The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? 62
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 62
The advent of biosimilars for the treatment of diabetes: current status and future directions 60
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients 55
Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. 53
Hidradenitis suppurativa and psoriasis: the odd couple 50
Vitiligo-like Lesions and COVID-19: Case Report and Review of Vaccination- and Infection-Associated Vitiligo 49
Non-Motherhood between Obligation and Choice: Statistical Analysis Based on Permutation Tests of Spontaneous and Induced Abortion Rates in the Italian Context 47
Hidradenitis Suppurativa in Patients with HIV: A Scoping Review 45
Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project 39
null 37
null 28
null 24
null 19
null 18
null 17
Totale 4.544
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.109
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.109
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021219 0 0 0 0 0 10 19 20 34 28 1 107
2021/2022380 2 23 2 4 16 8 46 5 24 83 33 134
2022/2023945 71 107 37 89 79 94 14 37 378 5 24 10
2023/2024292 17 30 27 31 30 93 15 5 3 14 1 26
2024/20251.110 26 14 19 63 56 44 45 217 264 96 104 162
2025/20261.251 214 219 258 220 323 17 0 0 0 0 0 0
Totale 4.544